(R)-3-hydroxy-3-phenylpropanamide | 24506-17-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-3-hydroxy-3-phenylpropanamide
• 英文别名: (R)-3-phenyl-3-hydroxypropanamide；ethyl (R)-3-hydroxy-3-phenylbutanoate；(R)-3-hydroxy-3-phenyl-propionic acid amide；(R)-3-Hydroxy-3-phenyl-propionsaeure-amid；(3R)-3-hydroxy-3-phenylpropanamide
• CAS: 24506-17-0
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: RHWRQKAVZMHQSH-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-3-hydroxy-3-phenylpropanamide 在 吡啶 、 lead(IV) acetate 作用下， 以80%的产率得到(S)-5-苯基-1,3-恶唑烷-2-酮
  参考文献：
  名称：

  A new facile chemoenzymatic synthesis of levamisole

  摘要：

  An efficient and facile chemoenzymatic synthesis of levamisole by employing lipase-mediated resolution of 3-hydroxy-3-phenylpropanenitrile followed by its conversion to beta-amino alcohol as the key intermediate is described. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.054
• 作为产物：
  描述：

  3-羟基-3-苯基丙酸甲酯 在 氨 作用下， 生成 (R)-3-hydroxy-3-phenylpropanamide
  参考文献：
  名称：

  McKenzie; Martin; Rule, Journal of the Chemical Society, 1914, vol. 105, p. 1586

  摘要：

  DOI：

文献信息

• Heterogeneous versus Homogeneous Copper(II) Catalysis in Enantioselective Conjugate-Addition Reactions of Boron in Water
  作者：Taku Kitanosono、Pengyu Xu、Shū Kobayashi

  DOI：10.1002/asia.201300997

  日期：2014.1

  reported for the conjugate addition of boron. Heterogeneous cat. 1 also gave high yields and enantioselectivities with some substrates and also gave the highest TOF (43 200 h−1) for an asymmetric conjugate‐addition reaction of boron. In addition, the catalyst systems were also applicable to the conjugate addition of boron to α,β,γ,δ‐unsaturated carbonyl compounds, although such reactions have previously

  我们已经开发了Cu II催化的硼在水中与α，β-不饱和羰基化合物和α，β，γ，δ-不饱和羰基化合物的对映体共轭加成反应。与先前报道的需要有机溶剂的Cu I催化相反，发现手性Cu II催化在水中有效地进行。已经开发了三种催化剂体系：催化剂。1：具有手性配体L 1的Cu（OH）2；猫。2：具有配体L1的Cu（OH）2和乙酸；和猫。3：具有配体L1的Cu（OAc）2。而猫。1是异构系统，猫。2和猫。3是同质系统。我们测试了27种α，β-不饱和羰基化合物和α，β-不饱和腈化合物，包括无环和环状α，β-不饱和酮，无环和环状β，β-二取代的烯酮，无环和环状α，β-不饱和酯（包括其β，β-二取代形式）和无环α，β-不饱和酰胺（包括其β，β-二取代形式）。我们找到那只猫。2和猫。图3显示了几乎所有底物的高产率和对映选择性。值得注意的是，没有报道过能以高收率和高对映选择性耐受所有这些底物的催化剂。异类猫。1
• Strengthening the Combination between Enzymes and Metals in Aqueous Medium: Concurrent Ruthenium-Catalyzed Nitrile Hydration - Asymmetric Ketone Bioreduction
  作者：Elisa Liardo、Rebeca González-Fernández、Nicolás Ríos-Lombardía、Francisco Morís、Joaquín García-Álvarez、Victorio Cadierno、Pascale Crochet、Francisca Rebolledo、Javier González-Sabín

  DOI：10.1002/cctc.201801005

  日期：2018.10.23

  ruthenium/ketoreductase catalytic system has been developed for the conversion of β‐ketonitriles into optically active β‐hydroxyamides through an unprecedented hydration/bioreduction cascade process in aqueous medium working in concurrent mode. The ketoreductase‐mediated ketone reduction took place with exquisite stereoselectivity and it was simultaneous to the nitrile hydration promoted by the ruthenium

  已经开发了双钌/酮还原酶催化系统，该催化系统通过在空运的介质中以前所未有的水合/生物还原级联过程，将β-酮腈转化为光学活性的β-羟酰胺，并发工作。酮还原酶介导的酮还原反应具有出色的立体选择性，并且与钌催化剂促进的腈水合反应同时进行。发生了整体转化：（i）使用市售的催化体系（ii）在温和的反应条件下，（iii）具有高转化度和出色的立体选择性，以及（iv）无需分离中间体和高最终产物产量。
• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20140135308A1

  公开（公告）日：2014-05-15

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；当（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C（R7）2，（x）X1为C（R7）2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，对于抑制脂质激酶包括p110 alpha和其他PI3K的亚型以及治疗由脂质激酶介导的癌症等疾病有用。公开了使用公式I化合物的方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件。
• Benzoxepin pi3k inhibitor compounds and methods of use
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2784078A1

  公开（公告）日：2014-10-01

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  式 I 的苯氧西泮化合物，包括其立体异构体、几何异构体、同分异构体、溶 剂、代谢物和药学上可接受的盐，其中：Z1 是 CR1 或 N；Z2 是 CR2 或 N；Z3 是 CR3 或 N；Z4 是 CR4 或 N；以及 其中：(i) X1 是 N，X2 是 S；(ii) X1 是 S，X2 是 N；(iii) X1 是 CR7，X2 是 S；(iv) X1 是 S，X2 是 CR7；(v) X1 是 NR8，X2 是 N，(vi) X1 是 N，X2 是 NR8，(vii) X1 是 CR7，X2 是 O，(viii) X1 是 O，X2 是 CR7，(ix) X1 是 CR7，X2 是 C(R7)2，(x) X1 是 C(R7)2，X2 是 CR7；(xi) X1 是 N，X2 是 O，或 (xii) X1 是 O，X2 是 N，这些化合物可用于抑制脂质激酶，包括 p110 alpha 和 PI3K 的其他同工型，以及治疗由脂质激酶介导的疾病，如癌症。公开了使用式 I 化合物体外、原位和体内诊断、预防或治疗哺乳动物细胞中的此类疾病或相关病理状况的方法。
• Enantioselective reduction of β-keto amides by the fungus Mortierella isabellina
  作者：Margarita Quirós、Francisca Rebolledo、Ramón Liz、Vicente Gotor

  DOI：10.1016/s0957-4166(97)00378-9

  日期：1997.9

  Incubations of the fungus Mortierella isabellina NRRL 1757 with -3-oxo-3-phenylpropanamide, 3-oxobutanamide and with some of their N-alkyl derivatives afford the corresponding (S)-3-hydroxyamides, usually in high chemical yields and enantiomeric excesses. (C) 1997 Elsevier Science Ltd.